PubRank

W Wurst

Author PubWeight™ 99.32‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Two lineage boundaries coordinate vertebrate apical ectodermal ridge formation. Genes Dev 2000 3.47
2 Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat Genet 1998 3.42
3 Rescue of the En-1 mutant phenotype by replacement of En-1 with En-2. Science 1995 3.37
4 Sequence interpretation. Functional annotation of mouse genome sequences. Science 2001 2.54
5 Targeted disruption of the trkB neurotrophin receptor gene results in nervous system lesions and neonatal death. Cell 1993 2.52
6 Establishment of a gene-trap sequence tag library to generate mutant mice from embryonic stem cells. Nat Genet 2000 2.22
7 Fate of midbrain dopaminergic neurons controlled by the engrailed genes. J Neurosci 2001 1.99
8 The mouse Engrailed-1 gene and ventral limb patterning. Nature 1996 1.98
9 The mouse Pax2(1Neu) mutation is identical to a human PAX2 mutation in a family with renal-coloboma syndrome and results in developmental defects of the brain, ear, eye, and kidney. Proc Natl Acad Sci U S A 1996 1.77
10 The caudal limit of Otx2 expression positions the isthmic organizer. Nature 1999 1.64
11 Neuroprotective and neurodegenerative effects of the chronic expression of tumor necrosis factor α in the nigrostriatal dopaminergic circuit of adult mice. Exp Neurol 2010 1.60
12 Parkin is transcriptionally regulated by ATF4: evidence for an interconnection between mitochondrial stress and ER stress. Cell Death Differ 2010 1.52
13 Abnormal embryonic cerebellar development and patterning of postnatal foliation in two mouse Engrailed-2 mutants. Development 1994 1.51
14 Development of dopaminergic neurons in the mammalian brain. Cell Mol Life Sci 2006 1.48
15 Targeted mutagenesis of Lis1 disrupts cortical development and LIS1 homodimerization. Proc Natl Acad Sci U S A 2001 1.44
16 Creatine improves health and survival of mice. Neurobiol Aging 2007 1.31
17 An induction gene trap screen in embryonic stem cells: Identification of genes that respond to retinoic acid in vitro. Proc Natl Acad Sci U S A 1996 1.18
18 The winged helix transcription factor Fkh10 is required for normal development of the inner ear. Nat Genet 1998 1.18
19 The nuclear form of phospholipid hydroperoxide glutathione peroxidase is a protein thiol peroxidase contributing to sperm chromatin stability. Mol Cell Biol 2005 1.15
20 Conditional mouse mutants highlight mechanisms of corticotropin-releasing hormone effects on stress-coping behavior. Mol Psychiatry 2008 1.15
21 Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J 2006 1.12
22 A role for the EphA family in the topographic targeting of vomeronasal axons. Development 2001 1.09
23 Distinct but redundant expression of the Frizzled Wnt receptor genes at signaling centers of the developing mouse brain. Neuroscience 2007 1.08
24 Expression of a novel mouse gene 'mbFZb' in distinct regions of the developing nervous system and the adult brain. Mech Dev 2001 1.01
25 Functional genomics by gene-trapping in embryonic stem cells. Methods Mol Biol 2002 1.01
26 Disruption of the murine PIASx gene results in reduced testis weight. J Mol Endocrinol 2005 1.01
27 The German Mouse Clinic: a platform for systemic phenotype analysis of mouse models. Curr Pharm Biotechnol 2009 1.01
28 Aquarius, a novel gene isolated by gene trapping with an RNA-dependent RNA polymerase motif. Dev Dyn 1998 0.98
29 Conditional corticotropin-releasing hormone overexpression in the mouse forebrain enhances rapid eye movement sleep. Mol Psychiatry 2009 0.96
30 Expression domains of murine ephrin-A5 in the pituitary and hypothalamus. Mech Dev 2000 0.94
31 Molecular characterisation of antidepressant effects in the mouse brain using gene expression profiling. J Psychiatr Res 2002 0.94
32 Regulation of the hypothalamic-pituitary-adrenocortical system in mice deficient for CRH receptors 1 and 2. Endocrinology 2001 0.94
33 Deletion of glucose transporter GLUT8 in mice increases locomotor activity. Behav Genet 2008 0.92
34 RNA interference in mice. Handb Exp Pharmacol 2007 0.92
35 Optimizing the intragastric pH as a supportive therapy in upper GI bleeding. Yale J Biol Med 1997 0.91
36 Coregulation of anterior and posterior mesendodermal development by a hairy-related transcriptional repressor. Genes Dev 2000 0.91
37 Endocannabinoids mediate acute fear adaptation via glutamatergic neurons independently of corticotropin-releasing hormone signaling. Genes Brain Behav 2008 0.90
38 Lack of influence of pantoprazole on the disposition kinetics of theophylline in man. Int J Clin Pharmacol Ther Toxicol 1991 0.88
39 Screening for novel pattern formation genes using gene trap approaches. Methods Enzymol 1993 0.87
40 Equipotent inhibition of gastric acid secretion by equal doses of oral or intravenous pantoprazole. Aliment Pharmacol Ther 1998 0.87
41 Differential disinhibition of the neonatal hypothalamic- pituitary-adrenal axis in brain-specific CRH receptor 1-knockout mice. Eur J Neurosci 2006 0.87
42 DJ-1-deficient mice show less TH-positive neurons in the ventral tegmental area and exhibit non-motoric behavioural impairments. Genes Brain Behav 2009 0.86
43 Expression of CRHR1 and CRHR2 in mouse pituitary and adrenal gland: implications for HPA system regulation. Endocrinology 2001 0.86
44 Cytotoxic T lymphocytes of the rat are predominantly restricted by RT1.A and not RT1.C-determined major histocompatibility class I antigens. Immunogenetics 1984 0.85
45 Regulation of the developing hypothalamic-pituitary-adrenal axis in corticotropin releasing hormone receptor 1-deficient mice. Neuroscience 2003 0.85
46 Lack of pharmacokinetic interaction of pantoprazole with diazepam in man. Br J Clin Pharmacol 1996 0.85
47 Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole. Aliment Pharmacol Ther 1996 0.85
48 Selective activation of the hypothalamic vasopressinergic system in mice deficient for the corticotropin-releasing hormone receptor 1 is dependent on glucocorticoids. Endocrinology 2000 0.84
49 The new topical steroid ciclesonide is effective in the treatment of allergic rhinitis. J Clin Pharmacol 1999 0.84
50 Lack of interaction between pantoprazole and digoxin at therapeutic doses in man. Int J Clin Pharmacol Ther 1995 0.84
51 Lack of pantoprazole drug interactions in man. Int J Clin Pharmacol Ther 1994 0.83
52 Pentagastrin-stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H+, K(+)-ATPase-inhibitor pantoprazole (BY1023/SK&F96022) in healthy volunteers. Z Gastroenterol 1990 0.83
53 Analysis of the rat major histocompatibility system by Southern blot hybridization. J Immunol 1985 0.83
54 Genetic mouse models for behavioral analysis through transgenic RNAi technology. Genes Brain Behav 2008 0.83
55 Pantoprazole lacks interaction with antipyrine in man, either by inhibition or induction. Int J Clin Pharmacol Ther 1994 0.83
56 Corticotropin-releasing hormone receptor type 1-deficiency enhances hippocampal serotonergic neurotransmission: an in vivo microdialysis study in mutant mice. Neuroscience 2002 0.82
57 Single intravenous administration of the H+, K(+)-ATPase inhibitor BY 1023/SK&F 96022--inhibition of pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man. Aliment Pharmacol Ther 1990 0.82
58 Expression of neurochondrin in the developing and adult mouse brain. Dev Genes Evol 2004 0.82
59 Genetic control of rodent midbrain dopaminergic neuron development in the light of human disease. Pharmacopsychiatry 2008 0.81
60 Lack of pharmacokinetic interaction between pantoprazole and diclofenac. Int J Clin Pharmacol Ther 1996 0.81
61 Acute stress regulation of neuroplasticity genes in mouse hippocampus CA3 area--possible novel signalling pathways. Mol Cell Neurosci 2008 0.81
62 Gene and enhancer trapping: mutagenic strategies for developmental studies. Curr Top Dev Biol 1993 0.81
63 Overview of clinical trials with urapidil. Am J Cardiol 1989 0.80
64 A novel family of repeat sequences in the mouse genome responsive to retinoic acid. Mamm Genome 1996 0.80
65 Transgenic overexpression of corticotropin releasing hormone provides partial protection against neurodegeneration in an in vivo model of acute excitotoxic stress. Neuroscience 2008 0.80
66 An induction gene trap for identifying a homeoprotein-regulated locus. Nat Biotechnol 2000 0.80
67 Amygdaloid pERK1/2 in corticotropin-releasing hormone overexpressing mice under basal and acute stress conditions. Neuroscience 2009 0.80
68 Conditional CRH overexpressing mice: an animal model for stress-elicited pathologies and treatments that target the central CRH system. Mol Psychiatry 2008 0.80
69 Acute haemodynamic effects of urapidil in patients with chronic left ventricular failure. Eur J Clin Pharmacol 1988 0.79
70 Effect of repeated oral administration of BY 1023/SK&F 96022--a new substituted benzimidazole derivative--on pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man. Aliment Pharmacol Ther 1990 0.79
71 Evidence for normal thymic export of lymphocytes and an intact RT6a gene in RT6 deficient diabetes prone BB-rats. Thymus 1989 0.79
72 Regulation of epidermal bullous pemphigoid antigen 1 (BPAG1) synthesis by homeoprotein transcription factors. J Invest Dermatol 1999 0.78
73 Pantoprazole lacks induction of CYP1A2 activity in man. Int J Clin Pharmacol Ther 1999 0.78
74 Restriction fragment-length polymorphism analysis of a second laboratory-derived mutant RT1 haplotype. Transplant Proc 1990 0.78
75 Characterization of the melanocortin-4-receptor nonsense mutation W16X in vitro and in vivo. Pharmacogenomics J 2011 0.77
76 Lack of interaction between pantoprazole and digoxin at therapeutic doses in man. Int J Clin Pharmacol Ther 1996 0.77
77 Lack of influence of pantoprazole on the disposition kinetics of theophylline in man. Int J Clin Pharmacol Ther 1996 0.77
78 Genetic analysis of susceptibility to diabetes mellitus in F2-hybrids between diabetes-prone BB and various MHC-recombinant congenic rat strains. J Autoimmun 1991 0.76
79 Lack of pantoprazole drug interactions in man: an updated review. Int J Clin Pharmacol Ther 1996 0.76
80 Pantoprazole does not interact with the pharmacokinetics of carbamazepine. Int J Clin Pharmacol Ther 1998 0.76
81 Lack of pharmacodynamic and pharmacokinetic interaction between pantoprazole and phenprocoumon in man. Eur J Clin Pharmacol 1996 0.76
82 Acute effects of urapidil on airway response in hypertensive patients with chronic obstructive pulmonary disease. Drugs 1990 0.76
83 Development of a capillary isoelectric focusing immunoassay to measure DJ-1 isoforms in biological samples. Anal Biochem 2013 0.76
84 Pharmacokinetics of pantoprazole in patients with end-stage renal failure. Nephrol Dial Transplant 1998 0.76
85 Considerations on genetic and environmental factors that contribute to resistance or sensitivity of mammals including humans to toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and related compounds. Part 1: Genetic factors affecting the toxicity of TCDD. Ecotoxicol Environ Saf 1997 0.76
86 Disruption of feeding behavior in CRH receptor 1-deficient mice is dependent on glucocorticoids. Neuroreport 2000 0.76
87 Phase I: transcranial echo contrast studies in healthy volunteers. Stroke 1995 0.76
88 Dose linearity of the pharmacokinetics of the new H+/K(+)-ATPase inhibitor pantoprazole after single intravenous administration. Int J Clin Pharmacol Ther 1994 0.76
89 Pantoprazole does not interact with nifedipine in man under steady-state conditions. Int J Clin Pharmacol Ther 1996 0.76
90 Dose linearity of the pharmacokinetics of the new H+/K(+)-ATPase inhibitor pantoprazole after single intravenous administration. Int J Clin Pharmacol Ther 1996 0.76
91 Generation of mice lacking DUF1220 protein domains: effects on fecundity and hyperactivity. Mamm Genome 2014 0.76
92 Pantoprazole and 24-hour intragastric acidity. Aliment Pharmacol Ther 1993 0.75
93 Pantoprazole has no influence on steady state pharmacokinetics and pharmacodynamics of metoprolol in healthy volunteers. Int J Clin Pharmacol Ther 1996 0.75
94 Functional and molecular genetic analysis of a group of rat class I major histocompatibility genes which might be homologous to H-2Qa. Folia Biol (Praha) 1985 0.75
95 Effect of urapidil on steady-state serum digoxin concentration in healthy subjects. Eur J Clin Pharmacol 1989 0.75
96 Treatment of mild hypertension with urapidil or captopril. Am J Hypertens 1988 0.75
97 Improved orthostatic dysregulation record after administration of a sustained-release form of urapidil. Int J Clin Pharmacol Ther Toxicol 1989 0.75
98 Phase I and pharmacokinetic study of the P-glycoprotein modulator dexniguldipine-HCL. Eur J Med Res 1997 0.75
99 Reduction of pentagastrin stimulated acid output: a suitable method to predict efficacy of an irreversible proton pump inhibitor in peptic ulcer disease? Int J Clin Pharmacol Ther Toxicol 1992 0.75
100 Lack of pantoprazole drug interactions in man: an updated review. Int J Clin Pharmacol Ther 1996 0.75
101 Analysis of a nonclassical class I gene of the rat major histocompatibility complex. Transplant Proc 1990 0.75
102 Pantoprazole does not interact with nifedipine in man under steady-state conditions. Int J Clin Pharmacol Ther 1996 0.75
103 Differential effects of two dihydropyridine calcium antagonists in humans. Clin Pharmacol Ther 1992 0.75
104 Analysis of the major histocompatibility genes that control susceptibility to diabetes mellitus in the BB rat. Transplant Proc 1989 0.75
105 Characterization of a class Ib gene of the rat major histocompatibility complex. Immunogenetics 1993 0.75
106 Efficacy of urapidil in the management of essential hypertension. A comparison with captopril. Drugs 1988 0.75
107 Antihypertensive efficacy of urapidil versus hydrochlorothiazide alone in patients with mild to moderate essential hypertension and of their combination in nonresponders to monotherapy. Drugs 1990 0.75
108 [Long-term antihypertensive therapy with urapidil. A 3-year open, multicenter trial of tolerance, safety and effectiveness]. Fortschr Med 1990 0.75
109 Lack of pharmacokinetic interaction between pantoprazole and diclofenac. Int J Clin Pharmacol Ther 1996 0.75
110 Pharmacokinetics of urapidil in patients with impaired renal function. Drugs 1990 0.75
111 [Metabolically neutral therapy of hypertension. An open, multicenter, prospective long-term study of the tolerance, safety and effectiveness of urapidil]. Fortschr Med 1988 0.75
112 Antibacterial active components in human urine after administration of penicillins. Infection 1979 0.75
113 Dose linearity and steady state pharmacokinetics of the new antiparkinson agent budipine after oral administration. Int J Clin Pharmacol Ther 2001 0.75
114 Tolerance, safety, and kinetics of the new antineoplastic compound dexniguldipine-HCl after oral administration: a phase I dose-escalation trial. Cancer Chemother Pharmacol 1995 0.75
115 Pantoprazole does not affect performance in traffic-related safety tests: a double-blind, randomised, placebo-controlled, crossover study in healthy volunteers. Clin Drug Investig 1998 0.75
116 Pantoprazole lacks interaction with antipyrine in man, either by inhibition or induction. Int J Clin Pharmacol Ther 1996 0.75
117 Targeted disruption of the mouse Npal3 gene leads to deficits in behavior, increased IgE levels, and impaired lung function. Cytogenet Genome Res 2009 0.75
118 Transcranial Doppler echo contrast studies using different colour processing modes. Acta Neurol Scand 1997 0.75
119 Bioavailability and pharmacokinetic characteristics of dexniguldipine-HCl, a new anticancer drug. Int J Clin Pharmacol Ther 1995 0.75